22521-79-5

Basic information

• Product Name: N-(4-ETHOXYPHENYL)-2-HYDROXYACETAMIDE
• Synonyms: N-(4-ETHOXYPHENYL)-2-HYDROXYACETAMIDE;N-(4-Ethoxyphenyl)glycolamide;p-Ethoxyglycolanilide;p-Glycolophenetidide
• CAS NO: 22521-79-5
• Molecular Formula: C₁₀H₁₃NO₃
• Molecular Weight: 195.22
• Mol File: 22521-79-5.mol
• Article Data: 1

Chemical Properties

• Melting Point: 149-150℃
• Boiling Point: 412.9°Cat760mmHg
• Flash Point: 203.5°C
• Appearance: /
• Density: 1.216
• Vapor Pressure: 1.48E-07mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(4-ETHOXYPHENYL)-2-HYDROXYACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-ETHOXYPHENYL)-2-HYDROXYACETAMIDE(22521-79-5)
• EPA Substance Registry System: N-(4-ETHOXYPHENYL)-2-HYDROXYACETAMIDE(22521-79-5)

Safety Data

• Hazardous Substances Data: 22521-79-5(Hazardous Substances Data)

Usage

General Description

N-(4-Ethoxyphenyl)-2-hydroxyacetamide, also known as ethoheptamide, is an organic compound with a chemical structure consisting of an ethyl group bonded to a phenyl ring and a hydroxyacetamide group. It is a non-opioid analgesic and antipyretic medication primarily used to relieve moderate to severe pain. It works by inhibiting the synthesis of prostaglandins, which are chemicals in the body that cause inflammation and pain. Ethoheptamide is commonly used in combination with other medications, such as paracetamol or codeine, to enhance its pain-relieving effects. However, due to its potential for abuse and addiction, it is classified as a Schedule III controlled substance in the United States. Additionally, its use is limited due to the risk of liver toxicity. Overall, N-(4-ethoxyphenyl)-2-hydroxyacetamide is a potent analgesic with potential side effects and limited clinical use.

InChI:InChI=1/C10H13NO3/c1-2-14-9-5-3-8(4-6-9)11-10(13)7-12/h3-6,12H,2,7H2,1H3,(H,11,13)

Upstream product

• 156-43-4 4-Ethoxyaniline 
• 62-44-2 4-ethoxyacetanilide 

Downstream Products

• 107415-93-0 ethoxycarbonyloxy-acetic acid p-phenetidide 

Relevant articles and documents

Oxidation of human cytochrome P450 1A2 substrates by Bacillus megaterium cytochrome P450 BM3

Cytochrome P450 enzymes (P450s or CYPs) are good candidates for biocatalysis in the production of fine chemicals, including pharmaceuticals. Despite the potential use of mammalian P450s in various fields of biotechnology, these enzymes are not suitable as biocatalysts due to their low stability, low catalytic activity, and limited availability. Recently, wild-type and mutant forms of bacterial P450 BM3 (CYP102A1) from Bacillus megaterium have been found to metabolize various. It has therefore been suggested that CYP102A1 may be used to generate the metabolites of drugs and drug candidates. In this report, we show that the oxidation reactions of typical human CYP1A2 substrates (phenacetin, ethoxyresorufin, and methoxyresorufin) are catalyzed by both wild-type and mutant forms of CYP102A1. In the case of phenacetin, CYP102A1 enzymes show only O-deethylation product, even though two major products are produced as a result of O-deethylation and 3-hydroxylation reactions by human CYP1A2. Formation of the metabolites was confirmed by HPLC analysis and LC-MS to compare the metabolites with the actual biological metabolites produced by human CYP1A2. The results demonstrate that CYP102A1 mutants can be used for cost-effective and scalable production of human CYP1A2 drug metabolites. Our computational findings suggest that a conformational change in the cavity size of the active sites of the mutants is dependent on activity change. The modeling results further suggest that the activity change results from the movement of several specific residues in the active sites of the mutants.